Shattuck Labs (STTK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and has a $28.00 price target.
Joseph Pantginis, an analyst at H.C. Wainwright, has given a Buy rating to Shattuck Labs, primarily due to the promising potential of their drug, SL-172154. The drug, currently undergoing phase 1a/b clinical trials, is showing encouraging signs of combating diseases notoriously difficult to treat, such as Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). SL-172154, a bifunctional fusion protein, is designed to target CD47 and act as a CD40 agonist. Pantginis believes that the drug’s dual-action mechanism helps overcome the limitations of traditional anti-CD47 treatments.
The initial data from the ongoing trials are particularly promising. They reveal anti-leukemic effects in previously untreated and recurring AML patients, both as a standalone treatment and in combination with azacitidine. The data also highlight the drug’s acceptable safety profile and effective dose-dependent results. Pantginis was further impressed by the drug’s differentiated pharmacodynamic activity, supporting the underlying mechanism of CD40 stimulation contributing to the observed responses. This, together with the early signs of anti-leukemic activity, helped solidify Pantginis’s Buy rating for Shattuck Labs.
In another report released on October 25, Berenberg Bank also maintained a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Shattuck Labs (STTK) Company Description:
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company’s product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Read More on STTK:
